Antibody drugs should exhibit not only high-binding affinity for their target antigens but also
favorable physicochemical drug-like properties. Such drug-like biophysical properties are …

Recombinant biopharmaceuticals including antigens, antibodies, hormones, cytokines,
single-chain variable fragments, and peptides have been used as vaccines, diagnostics and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in
viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for …

Proteins are a diverse class of biomolecules responsible for wide-ranging cellular functions,
from catalyzing reactions to recognizing pathogens. The ability to evolve proteins rapidly …

Antibody-antigen binding affinity lies at the heart of therapeutic antibody development:
efficacy is guided by specific binding and control of affinity. Here we present Graphinity, an …

The inability of antibodies to penetrate the blood-brain barrier (BBB) is a key limitation to
their use in diverse applications. One promising strategy is to deliver IgGs using a bispecific …

Early identification of antibody candidates with drug-like properties is essential for
simplifying the development of safe and effective antibody therapeutics. For subcutaneous …

Optimal combinations of paratopes assembled into a biparatopic antibody have the capacity
to mediate high-grade target cross-linking on cell membranes, leading to degradation of the …

Introduction Immunogenicity, the unwanted immune response triggered by therapeutic
antibodies, poses significant challenges in biotherapeutic development. This response can …

Although antibody variable regions mediate antigen-specific binding, they can also mediate
non-specific interactions with non-cognate antigens, impacting diverse immunological …